What Happened?
Shares of medical technology company iRhythm Technologies (NASDAQ: IRTC) jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and raised its full-year guidance. The company's revenue for the quarter reached $192.9 million, a 30.7% increase from the same period last year, beating analysts' projections by approximately $8.5 million. Furthermore, iRhythm significantly narrowed its losses, reporting an adjusted loss per share of $0.06, a substantial improvement from a loss of $1.26 per share in the same quarter of the previous year and well ahead of analysts' estimates. In light of the strong performance, the company increased its full-year 2025 revenue forecast to a midpoint of $737.5 million.
After the initial pop the shares cooled down to $191.60, up 3.9% from previous close.
Is now the time to buy iRhythm? Access our full analysis report here.
What Is The Market Telling Us
iRhythm’s shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 29 days ago when the stock gained 2.8% as news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations. The pharmaceutical and biotech sectors rallied for a second consecutive day following the announcement of a direct-to-consumer prescription drug selling website. A key driver for the optimism is a deal between Pfizer and the administration, allowing the company to avoid potential tariffs by reducing drug prices. This outcome is seen as a relief for the industry, which had braced for more severe measures. The move has reduced uncertainty in the sector, with other major players like Eli Lilly reportedly in negotiations for a similar agreement, signaling a potentially favorable new landscape for drugmakers.
iRhythm is up 114% since the beginning of the year, and at $191.60 per share, has set a new 52-week high. Investors who bought $1,000 worth of iRhythm’s shares 5 years ago would now be looking at an investment worth $903.77.
The biggest winners—Microsoft, Alphabet, Coca-Cola, Monster Beverage—were all riding powerful megatrends before Wall Street caught on. We’ve just identified an under-the-radar profitable growth stock positioned at the center of the AI boom. Get it FREE here before the crowd discovers it. GO HERE NOW.
